

## SEQUENCE LISTING

<110> Fuji Yakuhin Kogyo Kabushiki Kaisha

<120> Monoclonal Antibody against Canine Trypsin

<130> FJ-94PCT

<140>

<141>

<150> JP 10-236609

<151> 1998-08-10

<150> JP 11-63990

<151> 1999-03-10

<160> 5

<170> PatentIn Ver. 2.0

<210> 1

<211> 247

<212> PRT

<213> Dog Pancreas

<400> 1

Met Asn Pro Leu Leu Ile Leu Ala Phe Leu Gly Ala Ala Val Ala Thr  
1 5 10 15

Pro Thr Asp Asp Asp Asp Lys Ile Val Gly Gly Tyr Thr Cys Glu Glu  
20 25 30

Asn Ser Val Pro Tyr Gln Val Ser Leu Asn Ala Gly Tyr His Phe Cys  
35 40 45

Gly Gly Ser Leu Ile Ser Asp Gln Trp Val Val Ser Ala Ala His Cys  
50 55 60

Tyr Lys Ser Arg Ile Gln Val Arg Leu Gly Glu Tyr Asn Ile Asp Val  
65 70 75 80

Leu Glu Gly Asn Glu Gln Phe Ile Asn Ser Ala Lys Val Ile Arg His  
85 90 95

Pro Asn Tyr Asn Ser Trp Ile Leu Asp Asn Asp Ile Met Leu Ile Lys  
100 105 110

Leu Ser Ser Pro Ala Val Leu Asn Ala Arg Val Ala Thr Ile Ser Leu  
115 120 125

Pro Arg Ala Cys Ala Ala Pro Gly Thr Gln Cys Leu Ile Ser Gly Trp  
130 135 140

Gly Asn Thr Leu Ser Ser Gly Thr Asn Tyr Pro Glu Leu Leu Gln Cys  
145 150 155 160

Leu Asp Ala Pro Ile Leu Thr Gln Ala Gln Cys Glu Ala Ser Tyr Pro

165	170	175
Gly Gln Ile Thr Glu Asn Met Ile Cys Ala Gly Phe Leu Glu Gly Gly		
180	185	190
Lys Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Val Val Cys Asn Gly		
195	200	205
Glu Leu Gln Gly Ile Val Ser Trp Gly Tyr Gly Cys Ala Gln Lys Asn		
210	215	220
Lys Pro Gly Val Tyr Thr Lys Val Cys Asn Phe Val Asp Trp Ile Gln		
225	230	235
Ser Thr Ile Ala Ala Asn Ser		
245		
<210> 2		
<211> 246		
<212> PRT		
<213> Dog Pancreas		
<400> 2		
Met Lys Thr Phe Ile Phe Leu Ala Leu Leu Gly Ala Thr Val Ala Phe		
1	5	10
15		
Pro Ile Asp Asp Asp Asp Lys Ile Val Gly Gly Tyr Thr Cys Ser Arg		
20	25	30
Asn Ser Val Pro Tyr Gln Val Ser Leu Asn Ser Gly Tyr His Phe Cys		
35	40	45
Gly Gly Ser Leu Ile Asn Ser Gln Trp Val Val Ser Ala Ala His Cys		
50	55	60
Tyr Lys Ser Arg Ile Gln Val Arg Leu Gly Glu Tyr Asn Ile Ala Val		
65	70	75
80		
Ser Glu Gly Glu Gln Phe Ile Asn Ala Ala Lys Ile Ile Arg His		
85	90	95
Pro Arg Tyr Asn Ala Asn Thr Ile Asp Asn Asp Ile Met Leu Ile Lys		
100	105	110
Leu Ser Ser Pro Ala Thr Leu Asn Ser Arg Val Ser Ala Ile Ala Leu		
115	120	125
Pro Lys Ser Cys Pro Ala Ala Gly Thr Gln Cys Leu Ile Ser Gly Trp		
130	135	140
Gly Asn Thr Gln Ser Ile Gly Gln Asn Tyr Pro Asp Val Leu Gln Cys		
145	150	155
160		
Leu Lys Ala Pro Ile Leu Ser Asp Ser Val Cys Arg Asn Ala Tyr Pro		
165	170	175
Gly Gln Ile Ser Ser Asn Met Met Cys Leu Gly Tyr Met Glu Gly Gly		
180	185	190

Lys Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Val Val Cys Asn Gly  
 195 200 205

Glu Leu Gln Gly Val Val Ser Trp Gly Ala Gly Cys Ala Gln Lys Gly  
 210 215 220

Lys Pro Gly Val Ser Pro Lys Val Cys Lys Tyr Val Ser Trp Ile Gln  
 225 230 235 240

Gln Thr Ile Ala Ala Asn  
 245

<210> 3

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Designed  
 peptide to act as an immunogen

<400> 3

Cys Leu Ile Ser Gly Trp Gly Asn Thr Gln Ser Ile Gly Gln Asn Tyr  
 1 5 10 15

Pro Asp Val Leu  
 20

<210> 4

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Designed  
 peptide to act as an immunogen

<400> 4

Ile Val Gly Gly Tyr Thr Cys Ser Arg Asn Ser Val Pro Tyr Gln Val  
 1 5 10 15

Ser Leu Asn Ser  
 20

<210> 5

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Designed  
 peptide to act as an immunogen

<400> 5

Leu Gln Gly Val Val Ser Trp Gly Ala Gly Cys Ala Gln Lys Gly Lys  
 1 5 10 15

Pro Gly Val Ser  
 20